Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meditrina Pharmaceuticals has completed a global licensing agreement to make, develop and commercialize products under AstraZeneca's intelectual property and know-how regarding the use of aromatase inhibitors in combination with estrogen and progestin to treat endometriosis.
Subscribe to our email newsletter
This agreement expands Meditrina’s clinical stage product portfolio which currently includes Femathina (MPI- 674), an aromatase inhibitor (AI) that Meditrina is repurposing for the treatment of several serious women’s health conditions, including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).
John Patterson, executive director, R&D, AstraZeneca, said: “Anastrozole in combination with an estrogen and progestin in the area of women’s gynecologic indications represents a valid medical approach and sits well with Meditrina’s strategic focus and expertise.”